DARMSTADT, Germany--(BUSINESS WIRE)-- In alignment with the theme “Advancing quality through innovation” of the forthcoming annual meeting of the American Society of Clinical Oncology (ASCO, June 4-8 in Chicago), Merck Serono, a division of Merck KGaA, Darmstadt, Germany, will present new data from across its oncology franchise. Data included at the meeting will highlight the impact of KRAS testing and personalized therapy, an area of innovation which the company has championed. Further, additional data for Erbitux® (cetuximab) underscore the positive impact the treatment has had in metastatic colorectal cancer (mCRC) and head and neck cancer. New data for cilengitide, the first integrin inhibitor to reach Phase III development in oncology, and the MEK* inhibitor AS703026 will also be presented.
